Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC105 + Capecitabine in Metastatic Breast Cancer
NCT01326481Phase 2Completed
- Sponsor
- TRACON Pharmaceuticals, Inc.
- Start
- Jun 2011
- Primary completion
- Sep 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carotuximab in breast cancer, sponsored by TRACON Pharmaceuticals, Inc. Primary endpoint: Maximum Tolerated Dose at 1.5 years. Started Jun 2011; status: completed.
02
Drugs
carotuximab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01326481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01326481.